- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03150498
A Food Effects Study and Optional Multi Dose Study to Assess PK of BTD-001
A Phase 1 Cross-over Study to Determine Food Effects on the Pharmacokinetics of Oral BTD-001 and Metabolites in Healthy Volunteers, Followed by an Optional Multiple Dose Study to Assess Pharmacokinetics of Oral BTD-001
This is a single-centre, open-label study in healthy male and non-pregnant, non-lactating females. The study will consist of up to 2 parts; the decision to proceed to the optional second part will be made following review of Part 1 data.
Part 1 is a single dose, two period crossover to assess food affect of oral BTD-001.
Optional Part 2 is a non-randomised, single arm study multi dose design to evaluate PK profile of BTD-001
Study Overview
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Nottingham
-
Ruddington, Nottingham, United Kingdom, NG11 6JS
- Quotient Clinical
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy adult males and non-pregnant, non-lactating females aged 18-55 years old
- BMI between18.0-35.0 kg/m2 unless investigator deems not clinically significant
- Provide written consent
- Agrees to protocol specified contraception
Exclusion Criteria:
- Received any investigational treatment within last 3 months
- Subjects who are study site employees, or immediate family members of a study site or sponsor employee
- Subjects who have previously been enrolled in this study
- History of any drug or alcohol abuse in the past 2 years
- Regular alcohol consumption in males >21 units per week
- Current smokers and those who have smoked, including nicotine replacement or e-cigarates within the last 12 months.
- Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening
- Clinically significant abnormal lab results
- Positive drugs of abuse test result
- Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results
- Evidence of renal impairment at screening
- History of or current seizure disorder or history of syncope, unexplained loss of consciousness or seizure in the past 3 years
- Clinically significant medical/psychiatric history findings, or physical/neurological examination findings or significant history of or current suicidal ideation or behaviour
- History of or current significant pulmonary, cardiac, renal, hepatic, chronic respiratory, gastrointestinal, neurological or psychiatric disease, substance dependence, porphyria, malignancy (with exception of local cutaneous squamous or basal cell carcinomas or local cervical squamous cell cancer resolved after resection) or hypothyroidism
- Subjects with QT interval corrected for heart rate according to Fridericia's formula of >430 msec in males and >450 msec in females
- Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients
- Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hayfever is allowed unless it is active
- Donation or loss of greater than 400 mL of blood within the previous 3 months Subjects who are taking, or have taken, any prescribed or over-the-counter drug (other than up to 4 g per day paracetamol,hormone replacement therapy and hormonal contraception) or herbal remedies
- Failure to satisfy the investigator of fitness to participate for any other reason
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BTD-001 (fed)
|
BTD-001 in fed vs fasted state
|
Experimental: BTD-001 (fasted)
|
BTD-001 in fed vs fasted state
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1 & Part 2 - Cmax of BTD-001 and major metabolites
Time Frame: [Maximum 30 days]
|
Maximum Observed Plasma Concentration
|
[Maximum 30 days]
|
Part 1 & Part 2 - Tmax of BTD-001 and major metabolites
Time Frame: [Maximum 30 days]
|
Time to Maximum Observed Plasma Concentration
|
[Maximum 30 days]
|
Part 1 & Part 2 - AUC(0-last): of BTD-001 and major metabolites
Time Frame: [Maximum 30 days]
|
Area Under the Curve for Observed Plasma Concentration
|
[Maximum 30 days]
|
Part 1 & Part 2 - T1/2 of BTD-001 and major metabolites
Time Frame: [Maximum 30 days]
|
elimination half-life
|
[Maximum 30 days]
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Physical Examination
Time Frame: [Maximum 30 days]
|
Safety and tolerability of BTD-001 by assessing physical examination
|
[Maximum 30 days]
|
Vital Signs
Time Frame: [Maximum 30 days]
|
Safety and tolerability of BTD-001 by assessing vital signs
|
[Maximum 30 days]
|
ECG
Time Frame: [Maximum 30 days]
|
Safety and tolerability of BTD-001 by assessing ECG
|
[Maximum 30 days]
|
Adverse Events
Time Frame: [Maximum 30 days]
|
Safety and tolerability of BTD-001 by assessing AEs
|
[Maximum 30 days]
|
Safety Lab Test
Time Frame: [Maximum 30 days]
|
Safety and tolerability of BTD-001 by assessing safety lab tests
|
[Maximum 30 days]
|
Likert Scales
Time Frame: [Maximum 30 days]
|
To assess BTD-001 withdrawal in healthy volunteers
|
[Maximum 30 days]
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Karolinska Sleepiness Scale
Time Frame: [Maximum 30 days]
|
To assess sleepiness using the KSS
|
[Maximum 30 days]
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- BTD-001 HV104
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on BTD-001
-
Balance TherapeuticsCompletedIdiopathic Hypersomnia | Narcolepsy Without CataplexyUnited States
-
Balance TherapeuticsCompletedMolecular Mechanisms of Pharmacological ActionUnited Kingdom
-
Toll Biotech Co. Ltd. (Beijing)Recruiting
-
Patagonia Pharmaceuticals, LLCCompletedCongenital IchthyosisUnited States
-
IntegoGen, LLCWithdrawnHidradenitis SuppurativaUnited States
-
Frontera TherapeuticsRecruitingBiallelic RPE65 Mutation-associated Retinal DystrophyChina
-
JANSSEN Alzheimer Immunotherapy Research & Development...TerminatedAlzheimer's DiseaseUnited States
-
Heartseed Inc.RecruitingHeart Failure | Ischemic Heart DiseaseJapan
-
Longbio PharmaActive, not recruitingMyelodysplastic Syndrome (MDS)China
-
Astrogen, Inc.RecruitingAutism Spectrum DisorderKorea, Republic of